22 April,2022 04:35 PM IST | New Delhi | IANS
Representation Pic
The expert panel of India's apex drug regulator recommended grant of emergency use authorisation to Covid vaccine Corbevax for those in the 5-12 years age bracket.
According to a source familiar with the development, the Subject Expert Committee has recommended Drug Controller General of India grant the emergency use authorisation to Hyderabad-based Biological E's Corbevax for this age. However, the emergency use authorisation may be the subject of certain conditions, the source added.
Earlier in the day, the panel held a meeting to discuss the recommendations on restricted emergency use of Bharat Biotech's Covaxin and Biological E's Corbevax vaccines among children aged 5-12.
The SEC has sent the recommendations to the DCGI. After the DCGI's nod to the recommendation, the Union Health Ministry may give final approval to begin the vaccination for this age group.
ALSO READ
Bharat Biotech co-founder Dr. Krishna Ella awarded by Johns Hopkins
INSACOG data says 290 cases of Covid-19 variant KP.2, 34 cases of KP.1 detected
ICMR slams Covaxin study for poor methodology
2,100 cases of Covid sub-variant JN.1, its lineages detected in India: INSACOG
India reports 133 new COVID-19 cases, active tally at 1,389
Corbevax vaccine is India's first indigenously-developed protein sub-unit vaccine against Covid-19. This vaccine is currently being administered to children in the age group 12-14 years.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever